Effect of Prostaglandin E1 on Pulmonary Artery Pressure and Heart Failure Patients Cardiac Function in Patients with Pneumocardial Disease Complicated Cardiac Failure

OBJECTIVE To evaluate clinical therapeutic effects of prostagland in E1(PGE1) on hemodynamics and plasma BNP, ET-1 in cor pulmonale with heart failure and pulmonary hypertension. METHODS Eighty patients with cor pulmonale were randomly divided into treatment group(n=40, PGE1, 10 days, iv drip add conventional therapy including diuretic, enhancing myocardial contractility, anti-infection, correction of electrolyte and acid-base balance) and control group(n=40, conventional therapy). The changes of clinical manifestation such as heart rate(HR), respiratory rate(R), systolic blood pressure (SBP), diastolic blood pressure(DMP), urine output(UV), cardiac ultrasound results, arterial partial pressure of oxygenp(O₂), carbon dioxide partial pressurep(CO₂), plasma BNP, endothelin-1(ET-1) were measured before and after treatment. RESULTS After treatment, UV was significantly increased, SPAP, MPAP, DPAP, BNP and ET-1 were decreased. Compared with control group, there was significant difference in treatment group. CONCLUSION PGE1 on cor pulmonale with heart failure have significant effects, can significantly reduce pulmonary artery pressure, improve heart failure, may protect vascular endothelial function and reduce the level of BNP.